United States

Showing 311-320 of 345 grants

Title	Institution	Researcher	Program	Duration	Total Award Amount
In vivo analysis of human islet graft infiltration and its immunomodulation by antigen-specific therapy	Trustees of Columbia University in the City of New York	Remi Creusot	Cures	01-August-2022 to 31-July-2025	$699.995,75
Innovating Methods for AssessinG INsulin Action in Type ONe diabetes (IMAGINATiON)	Regents of the University of Colorado	Kristen Nadeau	Improving Lives	01-December-2021 to 31-December-2026	$445.816,29
EFFICACY AND SAFETY OF ONCE WEEKLY SEMAGLUTIDE IN ADULTS WITH OBESITY AND INADEQUATELY CONTROLLED TYPE 1 DIABETES USING HYBRID CLOSED-LOOP SYSTEM	Regents of the University of Colorado	Janet Snell-Bergeon	Improving Lives	01-November-2022 to 31-October-2026	$2.282.771,83
Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes	Regents of the University of Colorado	Jessica Kendrick	Improving Lives	01-October-2022 to 30-September-2026	$899.235,00
Understanding the role of scaffold microarchitecture on survival and function of stem cell-derived beta cells	Brown University	Tejal Desai	Cures	01-October-2022 to 30-September-2025	$474.741,58
Ultrafast Insulin-Pramlintide Co-formulations	Stanford University	Eric Appel	Improving Lives	01-September-2022 to 31-December-2026	$795.000,00
Local delivery of beta-cell survival factors and immunomodulators to enable highly efficient immunosuppression-free islet transplantation	Brown University	Tejal Desai	Cures	01-October-2022 to 01-October-2025	$714.837,80
Optimization of fast-acting venom insulins as therapeutic candidates for T1D	University of Utah	Helena Safavi	Improving Lives	01-September-2022 to 31-August-2026	$890.372,53
Deep Learning-based Analyses of Pancreatic Islet Beta-Cell Heterogeneity and MRI Pancreas Volume as Biomarkers to Improve Understanding of Type 1 Diabetes Progression	University of Florida	Sarah Kim	Cures	01-June-2022 to 31-May-2026	$750.000,00
Advanced Preclinical Development of iTOL-101, a Combination Investigational Product Composed of A Biotechnology-Derived Chimeric Streptavidin and A Fas Ligand (SA-FasL) Protein Bound to Biotinylated Hydrogel-Based Microparticles (Microgel) and Mixed with Deceased Donor Human Pancreatic Islets for the Treatment of Poorly-Controlled (or “Brittle”) Type 1 Diabetes	iTolerance, Inc.	Camillo Ricordi	Cures	01-June-2022 to 15-November-2026	$850.000,00